Cargando…

Profiling the immune landscape in mucinous ovarian carcinoma

OBJECTIVE. Mucinous ovarian carcinoma (MOC) is a rare histotype of ovarian cancer, with low response rates to standard chemotherapy, and very poor survival for patients diagnosed at advanced stage. There is a limited understanding of the MOC immune landscape, and consequently whether immune checkpoi...

Descripción completa

Detalles Bibliográficos
Autores principales: Meagher, Nicola S., Hamilton, Phineas, Milne, Katy, Thornton, Shelby, Harris, Bronwyn, Weir, Ashley, Alsop, Jennifer, Bisinoto, Christiani, Brenton, James D., Brooks-Wilson, Angela, Chiu, Derek S., Cushing-Haugen, Kara L., Fereday, Sian, Garsed, Dale W., Gayther, Simon A., Gentry-Maharaj, Aleksandra, Gilks, Blake, Jimenez-Linan, Mercedes, Kennedy, Catherine J., Le, Nhu D., Piskorz, Anna M., Riggan, Marjorie J., Shah, Mitul, Singh, Naveena, Talhouk, Aline, Widschwendter, Martin, Bowtell, David D.L., Candido dos Reis, Francisco J., Cook, Linda S., Fortner, Renée T., García, María J., Harris, Holly R., Huntsman, David G., Karnezis, Anthony N., Köbel, Martin, Menon, Usha, Pharoah, Paul D.P., Doherty, Jennifer A., Anglesio, Michael S., Pike, Malcolm C., Pearce, Celeste Leigh, Friedlander, Michael L., DeFazio, Anna, Nelson, Brad H., Ramus, Susan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374276/
https://www.ncbi.nlm.nih.gov/pubmed/36368129
http://dx.doi.org/10.1016/j.ygyno.2022.10.022
_version_ 1785078739133005824
author Meagher, Nicola S.
Hamilton, Phineas
Milne, Katy
Thornton, Shelby
Harris, Bronwyn
Weir, Ashley
Alsop, Jennifer
Bisinoto, Christiani
Brenton, James D.
Brooks-Wilson, Angela
Chiu, Derek S.
Cushing-Haugen, Kara L.
Fereday, Sian
Garsed, Dale W.
Gayther, Simon A.
Gentry-Maharaj, Aleksandra
Gilks, Blake
Jimenez-Linan, Mercedes
Kennedy, Catherine J.
Le, Nhu D.
Piskorz, Anna M.
Riggan, Marjorie J.
Shah, Mitul
Singh, Naveena
Talhouk, Aline
Widschwendter, Martin
Bowtell, David D.L.
Candido dos Reis, Francisco J.
Cook, Linda S.
Fortner, Renée T.
García, María J.
Harris, Holly R.
Huntsman, David G.
Karnezis, Anthony N.
Köbel, Martin
Menon, Usha
Pharoah, Paul D.P.
Doherty, Jennifer A.
Anglesio, Michael S.
Pike, Malcolm C.
Pearce, Celeste Leigh
Friedlander, Michael L.
DeFazio, Anna
Nelson, Brad H.
Ramus, Susan J.
author_facet Meagher, Nicola S.
Hamilton, Phineas
Milne, Katy
Thornton, Shelby
Harris, Bronwyn
Weir, Ashley
Alsop, Jennifer
Bisinoto, Christiani
Brenton, James D.
Brooks-Wilson, Angela
Chiu, Derek S.
Cushing-Haugen, Kara L.
Fereday, Sian
Garsed, Dale W.
Gayther, Simon A.
Gentry-Maharaj, Aleksandra
Gilks, Blake
Jimenez-Linan, Mercedes
Kennedy, Catherine J.
Le, Nhu D.
Piskorz, Anna M.
Riggan, Marjorie J.
Shah, Mitul
Singh, Naveena
Talhouk, Aline
Widschwendter, Martin
Bowtell, David D.L.
Candido dos Reis, Francisco J.
Cook, Linda S.
Fortner, Renée T.
García, María J.
Harris, Holly R.
Huntsman, David G.
Karnezis, Anthony N.
Köbel, Martin
Menon, Usha
Pharoah, Paul D.P.
Doherty, Jennifer A.
Anglesio, Michael S.
Pike, Malcolm C.
Pearce, Celeste Leigh
Friedlander, Michael L.
DeFazio, Anna
Nelson, Brad H.
Ramus, Susan J.
author_sort Meagher, Nicola S.
collection PubMed
description OBJECTIVE. Mucinous ovarian carcinoma (MOC) is a rare histotype of ovarian cancer, with low response rates to standard chemotherapy, and very poor survival for patients diagnosed at advanced stage. There is a limited understanding of the MOC immune landscape, and consequently whether immune checkpoint inhibitors could be considered for a subset of patients. METHODS. We performed multicolor immunohistochemistry (IHC) and immunofluorescence (IF) on tissue microarrays in a cohort of 126 MOC patients. Cell densities were calculated in the epithelial and stromal components for tumor-associated macrophages (CD68+/PD-L1+, CD68+/PD-L1−), T cells (CD3+/CD8−, CD3+/CD8+), putative T-regulatory cells (Tregs, FOXP3+), B cells (CD20+/CD79A+), plasma cells (CD20−/CD79a+), and PD-L1+ and PD-1+ cells, and compared these values with clinical factors. Univariate and multivariable Cox Proportional Hazards assessed overall survival. Unsupervised k-means clustering identified patient subsets with common patterns of immune cell infiltration. RESULTS. Mean densities of PD1+ cells, PD-L1− macrophages, CD4+ and CD8+ T cells, and FOXP3+ Tregs were higher in the stroma compared to the epithelium. Tumors from advanced (Stage III/IV) MOC had greater epithelial infiltration of PD-L1− macrophages, and fewer PD-L1+ macrophages compared with Stage I/II cancers (p = 0.004 and p = 0.014 respectively). Patients with high epithelial density of FOXP3+ cells, CD8+/FOXP3+ cells, or PD-L1− macrophages, had poorer survival, and high epithelial CD79a + plasma cells conferred better survival, all upon univariate analysis only. Clustering showed that most MOC (86%) had an immune depleted (cold) phenotype, with only a small proportion (11/76,14%) considered immune inflamed (hot) based on T cell and PD-L1 infiltrates. CONCLUSION. In summary, MOCs are mostly immunogenically ‘cold’, suggesting they may have limited response to current immunotherapies.
format Online
Article
Text
id pubmed-10374276
institution National Center for Biotechnology Information
language English
publishDate 2023
record_format MEDLINE/PubMed
spelling pubmed-103742762023-07-27 Profiling the immune landscape in mucinous ovarian carcinoma Meagher, Nicola S. Hamilton, Phineas Milne, Katy Thornton, Shelby Harris, Bronwyn Weir, Ashley Alsop, Jennifer Bisinoto, Christiani Brenton, James D. Brooks-Wilson, Angela Chiu, Derek S. Cushing-Haugen, Kara L. Fereday, Sian Garsed, Dale W. Gayther, Simon A. Gentry-Maharaj, Aleksandra Gilks, Blake Jimenez-Linan, Mercedes Kennedy, Catherine J. Le, Nhu D. Piskorz, Anna M. Riggan, Marjorie J. Shah, Mitul Singh, Naveena Talhouk, Aline Widschwendter, Martin Bowtell, David D.L. Candido dos Reis, Francisco J. Cook, Linda S. Fortner, Renée T. García, María J. Harris, Holly R. Huntsman, David G. Karnezis, Anthony N. Köbel, Martin Menon, Usha Pharoah, Paul D.P. Doherty, Jennifer A. Anglesio, Michael S. Pike, Malcolm C. Pearce, Celeste Leigh Friedlander, Michael L. DeFazio, Anna Nelson, Brad H. Ramus, Susan J. Gynecol Oncol Article OBJECTIVE. Mucinous ovarian carcinoma (MOC) is a rare histotype of ovarian cancer, with low response rates to standard chemotherapy, and very poor survival for patients diagnosed at advanced stage. There is a limited understanding of the MOC immune landscape, and consequently whether immune checkpoint inhibitors could be considered for a subset of patients. METHODS. We performed multicolor immunohistochemistry (IHC) and immunofluorescence (IF) on tissue microarrays in a cohort of 126 MOC patients. Cell densities were calculated in the epithelial and stromal components for tumor-associated macrophages (CD68+/PD-L1+, CD68+/PD-L1−), T cells (CD3+/CD8−, CD3+/CD8+), putative T-regulatory cells (Tregs, FOXP3+), B cells (CD20+/CD79A+), plasma cells (CD20−/CD79a+), and PD-L1+ and PD-1+ cells, and compared these values with clinical factors. Univariate and multivariable Cox Proportional Hazards assessed overall survival. Unsupervised k-means clustering identified patient subsets with common patterns of immune cell infiltration. RESULTS. Mean densities of PD1+ cells, PD-L1− macrophages, CD4+ and CD8+ T cells, and FOXP3+ Tregs were higher in the stroma compared to the epithelium. Tumors from advanced (Stage III/IV) MOC had greater epithelial infiltration of PD-L1− macrophages, and fewer PD-L1+ macrophages compared with Stage I/II cancers (p = 0.004 and p = 0.014 respectively). Patients with high epithelial density of FOXP3+ cells, CD8+/FOXP3+ cells, or PD-L1− macrophages, had poorer survival, and high epithelial CD79a + plasma cells conferred better survival, all upon univariate analysis only. Clustering showed that most MOC (86%) had an immune depleted (cold) phenotype, with only a small proportion (11/76,14%) considered immune inflamed (hot) based on T cell and PD-L1 infiltrates. CONCLUSION. In summary, MOCs are mostly immunogenically ‘cold’, suggesting they may have limited response to current immunotherapies. 2023-01 2022-11-08 /pmc/articles/PMC10374276/ /pubmed/36368129 http://dx.doi.org/10.1016/j.ygyno.2022.10.022 Text en https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Meagher, Nicola S.
Hamilton, Phineas
Milne, Katy
Thornton, Shelby
Harris, Bronwyn
Weir, Ashley
Alsop, Jennifer
Bisinoto, Christiani
Brenton, James D.
Brooks-Wilson, Angela
Chiu, Derek S.
Cushing-Haugen, Kara L.
Fereday, Sian
Garsed, Dale W.
Gayther, Simon A.
Gentry-Maharaj, Aleksandra
Gilks, Blake
Jimenez-Linan, Mercedes
Kennedy, Catherine J.
Le, Nhu D.
Piskorz, Anna M.
Riggan, Marjorie J.
Shah, Mitul
Singh, Naveena
Talhouk, Aline
Widschwendter, Martin
Bowtell, David D.L.
Candido dos Reis, Francisco J.
Cook, Linda S.
Fortner, Renée T.
García, María J.
Harris, Holly R.
Huntsman, David G.
Karnezis, Anthony N.
Köbel, Martin
Menon, Usha
Pharoah, Paul D.P.
Doherty, Jennifer A.
Anglesio, Michael S.
Pike, Malcolm C.
Pearce, Celeste Leigh
Friedlander, Michael L.
DeFazio, Anna
Nelson, Brad H.
Ramus, Susan J.
Profiling the immune landscape in mucinous ovarian carcinoma
title Profiling the immune landscape in mucinous ovarian carcinoma
title_full Profiling the immune landscape in mucinous ovarian carcinoma
title_fullStr Profiling the immune landscape in mucinous ovarian carcinoma
title_full_unstemmed Profiling the immune landscape in mucinous ovarian carcinoma
title_short Profiling the immune landscape in mucinous ovarian carcinoma
title_sort profiling the immune landscape in mucinous ovarian carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374276/
https://www.ncbi.nlm.nih.gov/pubmed/36368129
http://dx.doi.org/10.1016/j.ygyno.2022.10.022
work_keys_str_mv AT meaghernicolas profilingtheimmunelandscapeinmucinousovariancarcinoma
AT hamiltonphineas profilingtheimmunelandscapeinmucinousovariancarcinoma
AT milnekaty profilingtheimmunelandscapeinmucinousovariancarcinoma
AT thorntonshelby profilingtheimmunelandscapeinmucinousovariancarcinoma
AT harrisbronwyn profilingtheimmunelandscapeinmucinousovariancarcinoma
AT weirashley profilingtheimmunelandscapeinmucinousovariancarcinoma
AT alsopjennifer profilingtheimmunelandscapeinmucinousovariancarcinoma
AT bisinotochristiani profilingtheimmunelandscapeinmucinousovariancarcinoma
AT brentonjamesd profilingtheimmunelandscapeinmucinousovariancarcinoma
AT brookswilsonangela profilingtheimmunelandscapeinmucinousovariancarcinoma
AT chiudereks profilingtheimmunelandscapeinmucinousovariancarcinoma
AT cushinghaugenkaral profilingtheimmunelandscapeinmucinousovariancarcinoma
AT feredaysian profilingtheimmunelandscapeinmucinousovariancarcinoma
AT garseddalew profilingtheimmunelandscapeinmucinousovariancarcinoma
AT gaythersimona profilingtheimmunelandscapeinmucinousovariancarcinoma
AT gentrymaharajaleksandra profilingtheimmunelandscapeinmucinousovariancarcinoma
AT gilksblake profilingtheimmunelandscapeinmucinousovariancarcinoma
AT jimenezlinanmercedes profilingtheimmunelandscapeinmucinousovariancarcinoma
AT kennedycatherinej profilingtheimmunelandscapeinmucinousovariancarcinoma
AT lenhud profilingtheimmunelandscapeinmucinousovariancarcinoma
AT piskorzannam profilingtheimmunelandscapeinmucinousovariancarcinoma
AT rigganmarjoriej profilingtheimmunelandscapeinmucinousovariancarcinoma
AT shahmitul profilingtheimmunelandscapeinmucinousovariancarcinoma
AT singhnaveena profilingtheimmunelandscapeinmucinousovariancarcinoma
AT talhoukaline profilingtheimmunelandscapeinmucinousovariancarcinoma
AT widschwendtermartin profilingtheimmunelandscapeinmucinousovariancarcinoma
AT bowtelldaviddl profilingtheimmunelandscapeinmucinousovariancarcinoma
AT candidodosreisfranciscoj profilingtheimmunelandscapeinmucinousovariancarcinoma
AT cooklindas profilingtheimmunelandscapeinmucinousovariancarcinoma
AT fortnerreneet profilingtheimmunelandscapeinmucinousovariancarcinoma
AT garciamariaj profilingtheimmunelandscapeinmucinousovariancarcinoma
AT harrishollyr profilingtheimmunelandscapeinmucinousovariancarcinoma
AT huntsmandavidg profilingtheimmunelandscapeinmucinousovariancarcinoma
AT karnezisanthonyn profilingtheimmunelandscapeinmucinousovariancarcinoma
AT kobelmartin profilingtheimmunelandscapeinmucinousovariancarcinoma
AT menonusha profilingtheimmunelandscapeinmucinousovariancarcinoma
AT pharoahpauldp profilingtheimmunelandscapeinmucinousovariancarcinoma
AT dohertyjennifera profilingtheimmunelandscapeinmucinousovariancarcinoma
AT anglesiomichaels profilingtheimmunelandscapeinmucinousovariancarcinoma
AT pikemalcolmc profilingtheimmunelandscapeinmucinousovariancarcinoma
AT pearcecelesteleigh profilingtheimmunelandscapeinmucinousovariancarcinoma
AT friedlandermichaell profilingtheimmunelandscapeinmucinousovariancarcinoma
AT defazioanna profilingtheimmunelandscapeinmucinousovariancarcinoma
AT nelsonbradh profilingtheimmunelandscapeinmucinousovariancarcinoma
AT ramussusanj profilingtheimmunelandscapeinmucinousovariancarcinoma